ArticleThe Journal of biological chemistry2016

The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.

Kenta Watanabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.